The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the potential ...
Drug regulatory authorities in various countries have established stringent limits on the residual nucleic acids in biological products. For example, the FDA mandates that the residual DNA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results